Sickle cell detection using a smartphone

Knowlton, Stephanie; Şencan, İkbal; Aytar, Yusuf; Khoory, Joseph; Heeney, Matthew M.; Ghiran, Ionita

doi:10.1038/srep15022

Cited by 117 publications

(108 citation statements)

References 40 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…SickleDex TM ) are not sensitive enough to detect the low levels of HbS typically found in newborn blood samples, are notoriously difficult to standardize and interpret, and are confounded by numerous comorbidities which effect the turbidity of blood samples19. Various modifications of conventional laboratory methods (e.g., lower-cost implementation of IEF20, or a microfluidics-based HE21) as well as novel diagnostic approaches (e.g., density-based separation of sickle RBCs in capillaries2223, or magnetic levitation-based smartphone platforms24) may reduce the cost of testing and/or may be performed at the point-of-care but continue to require highly trained personnel and rely on complex specialized equipment and electricity to operate. Rapid diagnostic tests for SCD based on conventional lateral flow immunoassay technology are instrument- and electricity-free and show great potential252627.…”

Section: Discussionmentioning

confidence: 99%

A Paper-Based Test for Screening Newborns for Sickle Cell Disease

Piety

George

Serrano

et al. 2017

Sci Rep

View full text Add to dashboard Cite

The high cost, complexity and reliance on electricity, specialized equipment and supplies associated with conventional diagnostic methods limit the scope and sustainability of newborn screening for sickle cell disease (SCD) in sub-Saharan Africa and other resource-limited areas worldwide. Here we describe the development of a simple, low-cost, rapid, equipment- and electricity-free paper-based test capable of detecting sickle hemoglobin (HbS) in newborn blood samples with a limit of detection of 2% HbS. We validated this newborn paper-based test in a cohort of 159 newborns at an obstetric hospital in Cabinda, Angola. Newborn screening results using the paper-based test were compared to conventional isoelectric focusing (IEF). The test detected the presence of HbS with 81.8% sensitivity and 83.3% specificity, and identified SCD newborns with 100.0% sensitivity and 70.7% specificity. The use of the paper-based test in a two-stage newborn screening process could have excluded about 70% of all newborns from expensive confirmatory testing by IEF, without missing any of the SCD newborns in the studied cohort. This study demonstrates the potential utility of the newborn paper-based test for reducing the overall cost of screening newborns for SCD and thus increasing the practicality of universal newborn SCD screening programs in resource-limited settings.

show abstract

Section: Discussionmentioning

confidence: 99%

A Paper-Based Test for Screening Newborns for Sickle Cell Disease

Piety

George

Serrano

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Different visible wavelengths of fluorescent signal can be measured using the smartphone-based imaging platform by configuring the suitable light sources and filter sets. Furthermore, we envision that 3D printing technology can be employed for fabricating integrated smartphone-based cell imaging system and to provide the necessary biological containment to allow its safe use out of a research lab (Knowlton et al 2015;Skandarajah et al 2014;Yafia et al 2015).…”

Section: Discussionmentioning

confidence: 99%

Mkit: A cell migration assay based on microfluidic device and smartphone

Yang

Peretz‐Soroka

et al. 2018

Biosensors and Bioelectronics

View full text Add to dashboard Cite

Mobile sensing based on the integration of microfluidic device and smartphone, so-called MS 2 technology, has enabled many applications over recent years, and continues to stimulate growing interest in both research communities and industries. In particular, it has been envisioned that MS 2 technology can be developed for various cell functional assays to enable basic research and clinical applications. Toward this direction, in this paper, we describe the development of a MS 2 -based cell functional assay for testing cell migration (the M kit ). The system is constructed as an integrated test kit, which includes microfluidic chips, a smartphone-based imaging platform, the phone apps for image capturing and data analysis, and a set of reagent and accessories for performing the cell migration assay. We demonstrated that the M kit can effectively measure purified neutrophil and cancer cell chemotaxis. Furthermore, neutrophil chemotaxis can be tested from a drop of whole blood using the M kit with red blood cell (RBC) lysis. The effects of chemoattractant dose and gradient profile on neutrophil chemotaxis were also tested using the M kit . In addition to research applications, we demonstrated the effective use of the M kit for on-site test at the hospital and for testing clinical samples from chronic obstructive pulmonary disease patient. Thus, this developed M kit provides an easy and integrated experimental platform for cell migration related research and potential medical diagnostic applications.

show abstract

“…Recent technological improvements have led to the development of a smartphone attachment called “SC Tester,” which under deoxygenated conditions can screen for sickled red blood cells (sRBCs) in a blood sample at a low cost [29]. In addition, the use of smartphones with medical applications has been shown to potentially lead to better treatment compliance especially in adolescent and young SCD patients [30].…”

Section: Milestonesmentioning

confidence: 99%

Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease

Ansari

Moufarrej

Pawliński

et al. 2017

Expert Review of Hematology

View full text Add to dashboard Cite

Introduction Sickle cell disease (SCD) is a devastating monogenic disorder that presents as a multisystem illness and affects approximately 100,000 individuals in the United States alone. SCD management largely focuses on primary prevention, symptomatic treatment and targeting of hemoglobin polymerization and red blood cell sickling. Areas covered This review will discuss the progress of SCD over the last few decades, highlighting some of the clinical (mainly cerebrovascular) and psychosocial challenges of SCD in the United States. In addition, focus will also be made on the evolving science and management of this inherited disease. Expert Commentary Until recently hydroxyurea (HU) has been the only FDA approved therapy for SCD. However, advancing understanding of SCD pathophysiology has led to multiple clinical trials targeting SCD related thrombo-inflammation, abnormal endothelial biology, increased oxidant stress and sickle cell mutation. Yet, despite advancing understanding, available therapies are limited. SCD also imposes great psychosocial challenges for the individual and the affected community, which has previously been under-recognized. This has created a pressing need for complementary adjuvant therapies with repurposed and novel drugs, in addition to the establishment of comprehensive clinics focusing on both the medical treatment and the psychosocial issues associated with SCD.

show abstract

Sickle cell detection using a smartphone

Cited by 117 publications

References 40 publications

A Paper-Based Test for Screening Newborns for Sickle Cell Disease

A Paper-Based Test for Screening Newborns for Sickle Cell Disease

Mkit: A cell migration assay based on microfluidic device and smartphone

Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease

Contact Info

Product

Resources

About